SPATA31 subfamily B member 1, pseudogeneGenealiases: C9orf36B · FAM75B · SPATA31B1
Q-omics provides the consensus-scored SPATA31B1P profile across patient tissues and cancer cell-line models. SPATA31B1P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SPATA31B1P is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, SPATA31B1P RNA expression shows 9,075 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, HNSC, and TGCT as cancer lineages where SPATA31B1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31B1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31B1P survival associations across molecular data types. SPATA31B1P RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31B1P RNA expression–survival associations across cancer types. High SPATA31B1P expression shows unfavorable associations in DLBC, KIRC, UCEC and SKCM, but favorable associations in COAD and LIHC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify DLBC as the clearest survival context for SPATA31B1P RNA expression.
This table summarizes SPATA31B1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31B1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31B1P shows higher tumor expression in HNSC and KIRP. The HNSC box plot shows higher SPATA31B1P RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .016).
This table shows molecular features associated with SPATA31B1P in patient tissues and cancer cell lines. In patient samples, SPATA31B1P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
